Drug Approval
US FDA Approves BeOne’s TEVIMBRA-ZIIHERA Combination for First-Line HER2+ Gastroesophageal Cancer
TEVIMBRA plus ZIIHERA and chemotherapy is the first and only immunotherapy-based regimen to deliver more than two years of median OS in first-line HER2+ ...
August 27, 2026 | News
Caliway Secures FDA IND Clearance for CBL-514–Tirzepatide Phase 2 Trial, Advances SUPREME-01 Phase 3
FDA IND Clearance for CBL-0201WR—Caliway has cleared its Investigational New Drug application for CBL-0201WR, a Phase 2 trial evaluating CBL-514 in...
August 27, 2026 | News
Leads Biolabs’ Opamtistomig NDA Accepted in China for Advanced EP-NEC
Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the Center for Drug Evaluation (CDE) of China'...
August 24, 2026 | News
Singapore HSA Approves GSK’s Blenrep Combinations for Relapsed or Refractory Multiple Myeloma
Two head-to-head phase III trials demonstrated superior efficacy, including overall survival versus a daratumumab-based triplet in DREAMM-7 Blenrep, a f...
August 20, 2026 | News
JW Pharmaceutical’s Epaminurad Shows Statistical Superiority in Phase III Gout Trial
-JW Pharmaceutical (KRX:001060) announced that the multinational Phase 3 clinical trial of its gout treatment candidate ‘Epaminurad (code name U...
August 18, 2026 | News
China Approves Geneseeq’s PanTRKare as Companion Diagnostic for VELMARTO
NMPA granted approval to Geneseeq's PanTRKare™ NTRK1/2/3 Gene Fusion Detection Kit as a companion diagnostic for VELMARTO® (Eratrectini...
August 14, 2026 | News
Alteogen Signs Up to $365 Million Hybrozyme Licensing Deal for Subcutaneous Biologic
Alteogen grants exclusive rights to develop and commercialize a subcutaneous biologic product using Hybrozyme™-based hyaluronidase ALT-B4 Alteogen...
August 07, 2026 | News
Adneuris Licenses Cebranopadol Rights to Maruishi for Japan and South Korea
Agreement Grants Maruishi Rights for the Development and Commercialization of Cebranopadol for Pain in Japan and South Korea, Marking Adneuris' Second Ex...
August 07, 2026 | News
Biocon Launches Interchangeable YESAFILI Biosimilar to EYLEA in the U.S.
Yesafili™ (aflibercept-jbvf) now available in the United States as an U.S. FDA-approved interchangeable biosimilar to EYLEA 2 mg Potential ...
August 06, 2026 | News
Ractigen's World's First saRNA Therapy for Ocular Diseases Advances to Global Clinical Development Following U.S. FDA IND Clearance
RAG-1C achieves dual IND clearances from both U.S. FDA and China CDE, paving the way for global clinical development of the world's first saRNA therapy f...
August 03, 2026 | News
Ractigen Therapeutics Raises Over $31 Million to Advance saRNA Drug Pipeline
Ractigen Therapeutics, a clinical-stage biotechnology company pioneering small activating RNA (saRNA) therapeutics and advanced extrahepatic delivery syste...
July 31, 2026 | News
Glenmark Launches Generic Sugammadex Injection in the US
Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch1 of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL)...
July 30, 2026 | News
Kelun-Biotech Advances First Dual-Payload ADC into Clinical Trials for Solid Tumours
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical trial notice from t...
July 29, 2026 | News
OrbusNeich Enrols First Patient in Pivotal Japanese Trial of Coronary Drug-Coated Balloon
OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a multinational medical device comp...
July 28, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
